It looks like Novartis let a big one get away.
News & Analysis: Array BioPharma
These stocks were huge winners last week. But can their momentum continue?
Acquisitions made headlines, with Pfizer buying Array BioPharma and a private investor picking up Sotheby's.
The big drugmaker is spending more than $11 billion for the cancer-drug specialist.
Wall Street was in an optimistic mood on Monday morning.
Pfizer moves to acquire the cancer specialist in a deal valued at $11.4 billion.
Could the second half of the year be as much fun as the first?
Amicus Therapeutics and Array BioPharma are two top growth stocks to consider buying now.
Earnings, trial results, and acquisition activity were contributing factors to today's move higher for the stock market.
Positive clinical trial results gave investors a reason to cheer.